/RVX.TO
RVX.TO Stock - Resverlogix Corp.
Healthcare|BiotechnologyTSX
$0.10+5.26%
+$0.01 (+5.26%) • Dec 22
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.11
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RVX.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.10 – $0.10
TARGET (TP)$0.11
STOP LOSS$0.09
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.07
52W High$0.30
52W Low$0.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-476,746 | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,370,321 | $-12,749,000 | $-15,973,000 | $-14,569.5 | $-22,577,000 |
| Net Income | $-7,635,000 | $-3,610,000 | $-24,771,000 | $2,464.5 | $118.03M |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.01 | $-0.10 | $0.00 | $0.57 |
Company Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RVX.TOBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q1 22
No data
Q3 22
No data
Q4 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 14, 2025 | — | — | — | — |
Q2 2025 | May 14, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 12, 2024 | — | — | — | — |
Q3 2024 | Aug 14, 2024 | — | — | — | — |
Q2 2024 | May 14, 2024 | — | — | — | — |
Q1 2024 | Mar 26, 2024 | — | — | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.02 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.03 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.00 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.09 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about RVX.TO
What is RVX.TO's current stock price?
Resverlogix Corp. (RVX.TO) is currently trading at $0.10 per share. The stock has moved +5.26% today.
What is the analyst price target for RVX.TO?
No analyst price targets are currently available for this stock.
What sector is Resverlogix Corp. in?
Resverlogix Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.
What is RVX.TO's market cap?
Resverlogix Corp. has a market capitalization of $0.03 billion, making it a small-cap company.
Does RVX.TO pay dividends?
No, Resverlogix Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVCN.TO
Avicanna Inc.
$0.23
Mkt Cap: $0.0B
BCT.TO
BriaCell Therapeutics Corp.
$13.21
Mkt Cap: $0.0B
DOSE.CN
Rapid Dose Therapeutics Corp.
$0.13
Mkt Cap: $0.0B
GLAB.CN
Gemina Laboratories Ltd.
$0.08
Mkt Cap: $0.0B
HEM.V
Hemostemix Inc.
$0.09
Mkt Cap: $0.0B
LABS.TO
MediPharm Labs Corp.
$0.07
Mkt Cap: $0.0B
MBX.TO
Microbix Biosystems Inc.
$0.23
Mkt Cap: $0.0B
NARA.CN
Pangenomic Health Inc.
$0.68
Mkt Cap: $0.0B
PINK.V
Perimeter Medical Imaging AI, Inc.
$0.42
Mkt Cap: $0.0B
TELI.CN
Telescope Innovations Corp.
$0.34
Mkt Cap: $0.0B
Explore stocks similar to RVX.TO for comparison